RYBELSUS: payments to doctors
Payments that named RYBELSUS as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
- Total reported
- $52.3M
- Providers
- 150,288
- Transactions
- 1,605,787
- Average per transaction
- $33
The per-transaction average — $33 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 150,288 providers the average total is $348, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Novo Nordisk | $52,214,661 | 99.8% |
| Novo Nordisk AS | $91,079 | 0.2% |